Clinical need for bone grafting
===============================

Bones are organs of the skeletal system, providing shape, mechanical support and protection to the body, and facilitating movement. In addition, bones contribute to the mineral homeostasis of the body and have recently been found to participate in endocrine regulation of energy metabolism \[[@B1]\]. During development, bones form by two distinct processes \[[@B2]\]: intramembraneous and endochondral ossification. In intramembanous ossification, cells of the condensed mesenchymal tissue differentiate into osteoblasts and directly form bone. In contrast, endochondral ossification involves the formation of cartilaginous anlage, which then undergoes calcification and invasion by blood vessels, resulting in the formation of new bone by mesenchymal stem cells \[[@B3]\].

Adult bones are supplied by blood and constantly undergo remodeling, which allows adaptation to mechanical stresses, maintenance of bone health, and repair of small injuries. A recent study demonstrated very elegantly that the coupling between osteoclastic bone resorption and osteoblastic bone formation is needed to maintain bone health, and that both processes are mediated by tumor growth factor-β \[[@B4]\]. Similarly, coordinated responses of bone tissue, bone marrow, periosteum and surrounding soft tissues are needed for bone repair, which involves elements of both endochondral and intramembranous ossification \[[@B5]\]. A tight control of the balance between bone formation and resorption determines normal turnover of bone tissue throughout the lifetime.

Frequently, clinical situations arise where extensive injury, congenital malformations or diseases cause large bone defects, and reconstruction with tissue grafting is needed. Autologous grafts contain the essential components of bone regeneration - osteogenic cells, osteoinductive growth factors and bone-supporting matrix - but are not readily available in every situation. Other limitations include morbidity at the donor site (which often heals more slowly than the repair site) and difficulties in preparing anatomically shaped grafts from the harvested bone. Alternatives, including allogeneic bone transplantation, have their own limitations, such as tissue matching, disease transmission, batch variability, and an inability to survive and integrate following implantation \[[@B6]\]. Additionally, the large variability in bone defects, the huge complexity of bone architecture, and the high metabolic activity of bone, necessitating immediate blood supply, motivate the development of new treatment strategies \[[@B7]\].

Engineering viable human bone *in vitro*
========================================

Current models of bone formation *in vitro*are based on the paradigm that cellular differentiation and function can be modulated by the same factors known to play a role during embryonic development \[[@B8]\]. In order to engineer an environment supporting bone formation, combinations of biochemical and biophysical signals need to be presented to the cells in a three-dimensional setting in a way that allows cellular interactions with the surrounding cells and extracellular matrix (Figure [1](#F1){ref-type="fig"}, left). The complexity of signaling - with temporal and spatial gradients of molecular and physical factors affecting bone morphogenesis - presents significant challenges to engineering fully viable, functional bone.

![**Schematic representation of bone formation *in vitro***. Left: cells are growing attached to the scaffold surface, and sense microenvironmental signals. Middle: porous scaffolds offer support and a template for new tissue formation. Cell viability is maintained by medium perfusion through the scaffold interior. Right: dynamic culture in bioreactors enables control of medium flow and environmental parameters supporting *in vitro*osteogenesis.](scrt10-1){#F1}

One key component of the *in vitro*bone model is the scaffold, which provides a structural and logistic template for the developing tissue, and can markedly affect cell behavior (Figure [1](#F1){ref-type="fig"}, middle). Several types of porous scaffolds have been shown to support *in vitro*bone formation by human cells, including those made of ceramics \[[@B9],[@B10]\], native and synthetic polymers \[[@B11],[@B12]\] and composite materials \[[@B13]\].

Scaffold properties important for bone formation include: the size, distribution and shape of the pores \[[@B14]\]; surface roughness \[[@B15]\]; the presence of cell attachment sites \[[@B16]\]; and the biomechanics of both the material \[[@B17]\] and the scaffold structure. In general, the most suitable scaffolds for bone formation are those with large and interconnected pores (which facilitate cell infiltration and matrix deposition) and rough inner surfaces (which facilitate cell attachment), made of osteoconductive materials (such as bone protein and hydroxyapatite), and with mechanical properties similar to those of native bone (both to enable load-bearing and stimulate osteogenesis). Additional features of interest include anisotropic structure, capacity for vascularization, and processability into anatomically correct shapes. Scaffolds can also incorporate and modulate delivery of molecular signals controlling cellular functions \[[@B18]\].

Another key component of bone tissue engineering is the culture system or bioreactor. Bioreactor systems can be designed to control transport of nutrients and oxygen to cells in clinically sized constructs and provide lineage-specific biological stimuli in various regions of the graft \[[@B19]\]. Additionally, the development of functional, load-bearing characteristics of the graft would be enhanced by the application of biophysical stimulation in order to attain mechanical competence in both the cartilage and bone regions.

Advanced bioreactor designs maintain the physiological milieu in the cell microenvironment (pH, temperature, oxygen and nutrient delivery) by perfusion and conditioning of culture medium (Figure [1](#F1){ref-type="fig"}, right). Bioreactors can also be designed to recapitulate one or more of the developmentally relevant biophysical signals in a time-controlled manner. For example, increased mass transport and fluid shear by medium perfusion \[[@B20]-[@B22]\], and cyclic loading \[[@B23]\] have been shown to improve osteogenesis and enable formation of homogenous bone constructs. Ideally, a bioreactor system should be capable of coordinating biological, physiological and mechanical stimuli, and applying them in a spatially and temporally controlled manner to provide lineage-specific stimulation within clinically sized grafts.

The clinical and scientific utility of tissue engineering largely depends on our ability to predictably direct cells to differentiate into the right phenotypes in a spatially and temporally defined pattern. The control of environmental conditions provided through the design of bioreactors - in conjunction with scaffolds - can help gain more insight into the interplay of molecular and physical factors that guide the development of bone from various types of osteogenic cells. Understanding of the developmental process may then serve as feedback to the optimization of engineering parameters toward better graft designs, and towards the use of engineered grafts as models of development and disease.

Sources of human osteogenic cells
=================================

There are several basic considerations when choosing a cell source for bone tissue engineering: the choice between the patient\'s own (autologous) cells or the use of another person\'s (allogeneic) cells; the availability and ease of tissue harvesting with minimal donor site morbidity; the efficiency of cell isolation and cell yield; the use of primary osteogenic cells with limited potential for proliferation, or self-renewing stem cells; the use of cells that have both osteogenic and vasculogenic potential, to support the formation of vascularized bone; the homogeneity of the obtained cell population and controllable induction of the osteogenic phenotype; phenotype stability and cell safety after implantation; and the possibility of automation and the development of quality control measures for the generation of cells and grafts.

In most cases, cells are isolated from a tissue harvest and expanded *in vitro*prior to bone construct preparation. An expansion step increases the number of osteogenic cells (approximately 70 × 10^6^osteoblasts are needed to form 1 cm3 of new bone) \[[@B24]\], but could also be used for selection and enrichment of the appropriate cell population(s). Cells with high biosynthetic activity are desirable for enhanced bone formation *in vitro*and subsequent integration with the host tissue. Stable expression of the osteogenic phenotype could aid bone regeneration, and is critical in order to avoid non-specific tissue development. Several clinical reports of cell-based tissue engineering approaches for bone regeneration are summarized in Table [1](#T1){ref-type="table"}.

###### 

Overview of clinical studies in which tissue engineered grafts were applied for bone regeneration

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bone defect                                    Tissue-engineered graft preparation                                                                                                   Clinical evaluation                                                                                                                                                                                                                                       Reference
  ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  Segmental defects of long bones (3 patients)   Cultured bone marrow osteoprogenitors; seeding on hydroxyapatite scaffolds                                                            Callus formation and integration 2 months after surgery                                                                                                                                                                                                   \[[@B91]\]

  Large calvarial defect (1 patient)             Adipose stem cells in fibrin glue, with autologous cancellous bone                                                                    New bone formation and calvarial continuity 3 months after surgery                                                                                                                                                                                        \[[@B92]\]

  Maxillary sinus augmentation (2 patients)      Cultured mandibular periosteal cells; seeding and culture on polymer fleece under osteogenic conditions                               Tight interface of bone and dental implant, new mineralized trabecular bone and remnants of biomaterial 4 months after surgery                                                                                                                            \[[@B93]\]

  Maxillary sinus augmentation (27 patients)     Cultured mandibular periosteal cells; seeding and culture on polymer fleece in osteogenic conditions                                  18 patients: presence of mineralized trabecular bone, remnants of biomaterial and no resorption 3 months after surgery\                                                                                                                                   \[[@B94]\]
                                                                                                                                                                                       8 patients: absence of bone formation, resorption, connective tissue 3 months after surgery\                                                                                                                                                              
                                                                                                                                                                                       1 patient: infection after surgery, removal of the graft                                                                                                                                                                                                  

  Posterior mandible augmentation (1 patient)    Mandibular periosteal cells on polymer fleece                                                                                         Enhanced transverse ridge dimensions, dense lamellar bone 6 months after surgery                                                                                                                                                                          \[[@B95]\]

  Maxillary sinus augmentation (13 patients)     Group 1: cultured mandibular periosteal cells; seeding and culture on collagen scaffold in osteogenic conditions (8 patients)         Group 1: vital woven and partially mature lamellar bone 6 months after surgery, little remaining biomaterial                                                                                                                                              \[[@B96]\]

                                                 Group 2a: cultured maxillary osteoblasts; seeding and culture on natural bone mineral scaffold (2 patients)                           Group 2a: new bone and remnants of biomaterial at former sinus floor 8 months after surgery, poorly vascularized connective tissue, remnants of biomaterial                                                                                               

                                                 Group 2b: natural bone mineral scaffold alone (3 patients)                                                                            Group 2b: new bone and remnants of biomaterial 8 months after surgery; significantly lower bone density than in groups 1 and 2a                                                                                                                           

  Maxillary sinus augmentation (20 patients)     Group 1: autologous iliac crest bone (10 patients)                                                                                    Group 1: 29% bone resorption rate 3 months after surgery                                                                                                                                                                                                  \[[@B97]\]

                                                 Group 2: cultured mandibular periosteal cells; seeding and culture on polymer fleece in osteogenic conditions (10 patients)           Group 2: 90% graft resorption rate 3 months after surgery, graft density corresponding to connective tissue in all but one augmentation                                                                                                                   

  Maxillary sinus augmentation (3 patients)      Cultured mandibular periosteal cells; seeding and culture on polymer fleece in osteogenic conditions; implanted with xenograft bone   New fibrous bone and remnants of xenograft bone 4 months after surgery; some maturation into lamellar bone; presence of osteoclasts 6 months after surgery; increased bone height 18 months after surgery                                                 \[[@B98]\]

  Maxillary sinus augmentation (7 patients)      Cultured bone marrow stem cells seeding and 1-day culture on calcium phosphate ceramic scaffold                                       New bone formation and remnants of biomaterial 3 months after surgery; increased bone height 3 and 12 months after surgery                                                                                                                                \[[@B99]\]

  Lumbar segmental fusion (24 patients)          Group 1: autologous iliac crest cancellous bone (11 patients)\                                                                        Lower donor site morbidity in group 2; higher fusion rate in group 2 compared to group 1 in the period 3 to 9 months after surgery; comparable clinical and radiological results (80% fusion in group 1, 90% fusion in group 2) 12 months after surgery   \[[@B100]\]
                                                 Group 2: cultured mandibular periosteal cells; seeding and culture on polymer fleece in osteogenic conditions (13 patients)                                                                                                                                                                                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cells from bone tissue and periosteum
-------------------------------------

Adult bone tissue and periosteum can be used as sources of primary osteogenic cells \[[@B25]-[@B28]\]. Isolation techniques usually involve preparation of explant cultures from the dissected tissues, or enzymatic release of progenitor cells from the endosteal and periosteal layers (Figure [2a](#F2){ref-type="fig"}). Stepwise collagenase digestion has been used for the preparation of osteoblast-like populations with lower proportions of adherent stromal cells \[[@B25],[@B29]\]. In some studies, fetal bone tissue has been used as a potential alogeneic source due to fast cell proliferation and has demonstrated osteogenic potential \[[@B30]\].

![**Examples of human osteogenic cells growing *in vitro***. **(A)**Primary explant culture of bone cells. **(B)**Bone marrow mesenchymal stem cells. **(C)**Adipose stem cells. **(D)**Human embryonic stem cells (line H13) growing on mouse embryonic fibroblasts. Original magnification: 100×.](scrt10-2){#F2}

*In vitro*, between 20 and 40 population doublings have been reported for primary bone and periostal cells \[[@B31],[@B32]\]. Studies have indicated differences in proliferation rates of the bone cells isolated by different methods and originating from different donors, as well as age-related declines in cell proliferation \[[@B26],[@B27],[@B30]\]. Differences in the proliferation potentials of bone cells isolated from different sites have been observed \[[@B29],[@B33]\], similar to bone marrow stromal cells originating from different sites \[[@B34]\].

In most studies, the expression of osteogenic markers (for example, increased alkaline phosphatase activity, synthesis of osteopontin, bone sialoprotein, osteocalcin and extracellular matix calcification) has been noted in the presence of the osteogenic supplements 1,25-dihydroxy vitamin D3, dexamethasone, β-glycerophosphate and L-ascorbic acid \[[@B35],[@B36]\], but only a limited amount of work has directly compared the functional potentials of osteogenic cells isolated from different sources \[[@B37]\]. In addition to osteogenesis, it has been reported that periosteal and endosteal populations also exhibit chondrogenic and adipogenic differentiation potential \[[@B31],[@B32]\].

Primary human bone and periosteal cells cultured on porous scaffolds formed bone-like tissue \[[@B11],[@B38],[@B39]\]. In separate studies, bone constructs have been engineered from periosteal cells and used clinically to enhance healing of periodontal defects (Table [1](#T1){ref-type="table"}).

Taken together, these studies demonstrate that primary osteogenic cells can be isolated from tissues discarded during surgical procedures and used for *in vitro*studies \[[@B33]\], and suggest that harvests of small tissue volumes from relatively accessible sites (for example, jaw bones during dental implant placement) could potentially be used for cell isolation and preparation of autologous grafts up to several millimeters in diameter and length. In contrast, due to donor site morbidity \[[@B40]-[@B42]\] and limited proliferation of primary cells, it would be difficult to envision routine preparation of large autologous grafts (several centimeters in diameter and length) from primary bone or periosteum-derived cells (Table [1](#T1){ref-type="table"}). The applicability of such approaches will strongly depend on developing robust cell preparation procedures from source tissues that are inherently variable due to donor age, gender, health status, systemic conditions and genetic background.

Adult stem cells
----------------

Adult mesenchymal stem cells capable of differentiation into bone, cartilage, adipose, muscle, tendon, ligament and marrow stroma have been found in a variety of tissues, including bone marrow, adipose tissue, synovium, dental pulp, cord blood, umbilical cord and others \[[@B43]-[@B46]\]. For bone regeneration, the most studied source has been the bone marrow, as it was recognized early that its stroma contains bone marrow mesenchymal stem cells (BMSCs) capable of forming bone and cartilage \[[@B47]\]. Bone marrow transplantation is also being used clinically in combination with osteoconductive materials to augment bone healing \[[@B6],[@B48]\].

BMSCs are commonly isolated based on their adherence and growth on tissue culture plastics (Figure [2b](#F2){ref-type="fig"}). Alternatively, pure bone marrow aspirates can be used to immunoselect BMSCs using specific surface markers. The small initial numbers of immunoselected cells are then expanded in culture to obtain sufficient cell mass for therapeutic purposes. The number of stem cells (0.001 to 0.01% of the nucleated marrow cells) \[[@B43]\] varies between different patients and reportedly declines with patient age \[[@B46]\]. Additionally, marrow aspiration volume (up to 150 ml) and technique can influence the number of isolated stem cells \[[@B48]\]. BMSCs can, however, be culture-expanded to large numbers and have been reported to reach up to 50 population doublings *in vitro*\[[@B49]\]. Importantly, studies suggest that the osteogenic potential of BMSCs is maintained in older individuals \[[@B46]\], and appropriate conditions *in vitro*(for example, culture on collagen substrate, growth factor supplementation of culture media) \[[@B50],[@B51]\] can help maintain cell differentiation potential.

Adipose tissue stem cells (ASCs), discovered more recently \[[@B44]\], represent another attractive source for bone tissue engineering due to their accessibility and potential for differentiation into osteogenic, chondrogenic, adipogenic and endothelial lineages \[[@B52]\]. Lipoaspirate volumes can range from 100 ml to several liters and contain a relatively high frequency of ASCs (1 to 5% of isolated nucleated cells) \[[@B53]\]. Cell isolation protocols usually include density gradient centrifugation of the collagenase-digested tissue (lipoaspirate or minced adipose tissue) and culture of the adherent cell population (Figure [2c](#F2){ref-type="fig"}). Similar to BMSCs, the numbers of isolated stem cells are influenced by the tissue harvesting procedure, as well as the site of tissue harvesting (for example, arm, thigh, abdomen, breast) \[[@B52]\].

Several groups have reported the formation of bonelike constructs from BMSCs and ASCs cultured on porous scaffolds \[[@B54]-[@B56]\], and noted positive effects of dynamic bioreactor culture on cell distribution and matrix formation \[[@B12],[@B20],[@B21]\]. Recently, our group has reported engineering of fully viable, clinically sized, and precisely shaped temporomandibular joint grafts by culturing BMSCs on anatomically shaped scaffolds in specially designed \'anatomical\' bioreactors \[[@B57]\]. This study illustrates the feasibility of using adult stem cells for engineering functional human bone grafts, and underlines the importance of perfusion culture to support physiologic cell densities, as well as formation of dense, homogenously distributed bone matrix.

Survival of large engineered grafts after implantation remains an open question due to the need for immediate connection to the host vasculature, which is an unsolved problem of all tissue engineering. Various strategies for pre-vascularization are currently under investigation \[[@B7]\]. For example, Scherberich and colleagues \[[@B58]\] obtained bone constructs with intrinsic vascularization potential by culturing isolated adipose stromal vascular fractions on porous scaffolds in perfusion for 5 days. These efforts could enhance the survival of implanted grafts once the methods become available for the connection of the graft to the blood supply of the host.

A few clinical studies have reported on bone constructs prepared from adult stem cells and implanted to enhance bone regeneration. Importantly, adverse side effects of the transplanted cells have not been reported, and the authors suggested possible positive effects of transplanted cells on bone regeneration (Table [1](#T1){ref-type="table"}).

Differentiation potential and phenotype stability of adult stem cells
---------------------------------------------------------------------

Differentiation potentials of adult stem cells obtained from various sources are under investigation, as are the culture conditions required to achieve the functional properties of terminally differentiated cells. Another focus is determining correlations between the phenotypes of cultured cells and their potential for functional differentiation. Stem cells isolated from various tissues are frequently evaluated for the expression of surface antigens by flow cytometry \[[@B43],[@B45]\], and share common patterns between various BMSC preparations, and a highly conserved profile between ASC preparations \[[@B52]\]. In spite of the relative uniformity of marker expression, the cell potential to deposit bone matrix can vary quite significantly between different donors and cell populations \[[@B21],[@B59]\].

Simple models for evaluating the differentiation potential of cells are provided by micromass and pellet cultures. Pellets are prepared by centrifugation of several hundred thousand cells, and incubated in differentiation media for specific differentiation paths - in most cases osteogenic, chondrogenic and adipogenic. Micromass cultures are prepared by plating droplets of high cell density suspensions on tissue culture plates, which are also incubated in specific cell differentiation media. In both systems, high cell density helps mimic cell interactions and cell condensation events present during native development of cartilage and bone.

Osteogenesis and chondrogenesis can be measured quantitatively using molecular, biochemical and histological assays \[[@B12],[@B21]\]. Bone formation capacity can also be evaluated *in vivo*- for example, in ectopic bone formation models \[[@B60]\]. In a recent study, correlations between bone marker gene expression and functional osteogenesis assays have been made to construct a mathematical model for predicting the bone forming capacity of the synovial and periosteal stem cells \[[@B60]\]. In future, such models could possibly be implemented in culture protocols to help develop robust procedures for manufacturing bone grafts.

Several reports of long-term BMSC and ASC cultures (≥ 4 months, ≥ 30 doublings) have indicated changes in cell cycle kinetics and the possibility of abnormal karyotype development, leading to malignant cell transformation \[[@B61],[@B62]\]. These studies identified some limitations of *ex vivo*manipulation, which should be taken into consideration and explored further to ensure the biosafety of adult stem cells before their clinical application.

Embryonic stem cells and induced pluripotent stem cells
-------------------------------------------------------

Pluripotent human embryonic stem cells (ESCs) can form any tissue of the body and have exhibited an unsurpassed (possibly unlimited) potential for proliferation *in vitro*\[[@B63]\]. ESCs were first successfully isolated and cultured in 1998 by Thomson and colleagues \[[@B64]\], and have enormous value as a potential source of cells for regenerative medicine, as well as a model of early human development. In bone tissue engineering, ESCs could be used as a single source for the derivation of multiple lineages present in adult bone, including osteogenic cells, vascular cells, osteoclasts, nerve cells and others.

Compared to adult stem cells, ESCs require complex culture conditions: they are commonly derived from blastocyst-stage embryos and cultured on mitotically inactivated murine feeder cells in media supplemented with basic fibroblast growth factor and other factors \[[@B63]\]. ESCs grow in colonies, and are passaged as small aggregates by mechanical or enzymatic dissociation from the feeder cells. In recent years, progress has been made, and completely defined feeder-free conditions have been reported \[[@B65]\]. In an alternative approach, human feeder cells (for example, skin fibroblasts) have been used for ESC culture \[[@B66]\].

Similar to adult stem cells, pluripotent ESCs are characterized by the expression of specific surface antigens, including stage-specific embryonic antigen-4 (SSEA-4), tumor rejection antigens TRA-1-60 and TRA-1-81, and the absence of SSEA-1 \[[@B67]\]. Other markers associated with undifferentiated ESCs are high alkaline phosphatase and telomerase activities, and expression of transcription factors Oct4, Sox2 and Nanog, which are crucial for the maintenance of pluripotency \[[@B68]\]. A standard test for confirming human ESC differentiation potential *in vivo*is the formation of teratomas after cell injection in immunodeficient mice. Pluripotency can also be evaluated *in vitro*by inducing differentiation in embryoid bodies (aggregates of cells cultured in suspension) and observing formation of tissues from all three germ layers \[[@B67]\].

Spontaneous development of abnormal karyotypes and other genetic alterations have been observed during prolonged cultivation of ESCs \[[@B69],[@B70]\]. Therefore, frequent monitoring of the karyotype is recommended, and further studies are needed to ensure stability and safety of the ESC-derived progenitor populations before their potential use in regenerative medicine.

Recently, the prospect of using ESCs for autologous therapies has gained attention with reports of induced pluripotent stem cells derived from adult differentiated cells \[[@B71]\]. Induced pluripotent stem cells share many characteristics with ESCs, including morphology, proliferation, surface antigens, gene expression, epigenetic status and pluripotency. Development of safer alternatives for cell reprogramming (for example, excluding genetic manipulation) could potentially provide a cell source for autologous therapy \[[@B72]\]. Currently, however, these cells present a unique opportunity to study the development and progression of genetic diseases *in vitro*.

Osteogenesis of embryonic human stem cells
------------------------------------------

The pluripotent nature of ESCs presents a challenge to the development of efficient protocols for directing cells into specific lineages. The embryoid body step has been an integral part of many differentiation protocols, including osteogenic differentiation. Cells capable of osteogenesis have been found in mixed populations of progenitor cells present in embryoid bodies after 4 to 5 days of culture \[[@B73],[@B74]\], and populations arising from co-cultures with primary bone and periodontal ligament cells \[[@B75],[@B76]\]. A direct differentiation protocol excluding the embroid body step has also been tested, and seemed to enhance ESC osteogenesis *in vitro*\[[@B77]\].

Alternatively, induction and isolation of mesenchymal stem cells (MSCs) from ESCs has been attempted, and these MSC-like progenitors have been subsequently directed into the osteogenic lineage (mostly in monolayer culture). In one study, MSC-like progenitors have been obtained by mechanical isolation of spontaneously differentiated cells from ESC cultures, followed by longer culture in confluent monolayers \[[@B78]\]. In another study, co-culture with stromal cells was used to induce differentiation, followed by immunoselection of a MSC-like population \[[@B79]\]. More recently, exposure of ESCs to serum and growth factor supplemented media \[[@B80],[@B81]\] has been used to induce differentiation, and MSC-like progenitors have been expanded in a subsequent monolayer culture. Whereas these studies elucidate some of the factors involved in osteogenesis of ESCs, further work is needed to gain a better understanding of the developmental processes involved in specification to bone-forming cells, as well as to evaluate the stability and functionality of the obtained populations \[[@B82]\].

Genetically engineered osteogenic cells
---------------------------------------

*In vivo*implantation of stem cells genetically engineered to carry osteogenic genes has been shown to induce rapid bone formation, indicating the possibility of enhancing regenerative processes by combining cell and gene therapy strategies. It has been hypothesized that genetically modified cells exert both autocrine and paracrine effects, recruiting host cells to the site of implantation and resulting in enhanced osteogenesis \[[@B83]\]. Importantly, recruitment of host cells could allow for a reduced number of exogenous cells that need to be implanted. In many studies, adult stem cells have been engineered to express genes of the bone morphogenetic protein family (for example, *BMP2*, *BMP4*, and *BMP7*). Other genes of interest include those encoding transcription factors essential for osteoblast differentiation (for example, core binding factor α1 (Cbfa1), and Osterix), factors enhancing angiogenesis (for example, vascular endothelial growth factor), and bone formation antagonists (for example, noggin) for an additional level of control over bone formation, and combinations of several factors \[[@B83]\]. The challenges lay in efficiently delivering therapeutic genes into the cells without adenoviral and retroviral vectors - for example, by nucleofection (a form of electropermeabilization) - in order to increase safety and allow for the subsequent development of clinical applications.

Future prospects, clinical translation and regulation
=====================================================

In addition to scientific challenges, several manufacturing, safety and regulatory issues need to be addressed before cell-based therapies can become routine clinical practice for the treatment of bone defects. Recently, the conditions allowing clinical scale production of cells for therapeutic purposes have been evaluated, including the possibility of automated culture \[[@B84],[@B85]\]. Functional and structural criteria for bone grafts are not yet fully established, and might vary depending on the therapeutic purpose. In pre-clinical studies, load-bearing large animal models should generally be used to assess graft functionality, as research on small animals does not give relevant results due to major differences in graft size and healing properties.

Cell-based products are those requiring cell isolation, proliferation and differentiation, as well as application of supporting scaffolding materials. Under European Union regulations, cell-based products need to be manufactured in good manufacturing practice facilities under classic pharmaceutical standards \[[@B86],[@B87]\]. The regulation of cell-based products falls under the categories of \'human cell, tissue, and cellular and tissue based products\' \[[@B88],[@B89]\] in the USA, and \'advanced cell therapies\' in Europe as defined in \[[@B86]\]. In addition, the International Society for Stem Cell Research published *Guidelines for the Clinical Translation of Stem Cells*\[[@B90]\], which highlight the scientific, clinical, regulatory, ethical, and social issues to be addressed for cell-based products and services. These documents address the safety and use of therapeutic cells, and regulate the necessary evaluations and permissions for the sourcing of material, especially for cells of allogeneic origin (patient information, genetic and infection screening, written informed consent for donors).

As a general principle, stem cell-based approaches should be clinically competitive or superior to existing therapies. The risks of using cell-based products should be carefully evaluated with respect to the benefits of enhanced functional outcome, application of one single procedure, reduction of cost, and improved quality of life. Clinical trials should be based on a clear rationale and justification of the procedure (with supporting preclinical data and comparisons to existing treatments), and should include characterization of the product, description of administration (including drugs and surgery) and plans for clinical follow-up and adverse events reporting.

Conclusions
===========

Tissue-engineered bone constructs have the potential to alleviate the demand arising from the shortage of suitable autograft and allograft materials for augmenting bone healing. They also can serve as controllable *in vitro*models of high biological fidelity for studies of bone development, disease or regeneration. Each of the sources of osteogenic human cells - primary cells, MSCs, ESCs and induced pluripotent stem cells - has distinct advantages when used for bone tissue engineering, and the quest for an \'ideal\' cell source is still in progress.

Technologies are critical for unlocking the full biological potential of any cell type. To this end, advanced scaffolds (with molecular, structural and mechanical properties designed to mimic bone) and bioreactors (with environmental control and biophysical signaling for enhanced osteogenesis) are being developed to engineer bone grafts and to test the osteogenic capacity of stem cells. Because bone is a vascularized tissue that is actively remodeled through coordinated sequences of bone growth and resorbtion, the requirements are much more complex than \'just\' the formation of mineralized bone matrix. The need for a vascular compartment, as well as for coordinated activity of osteoblasts and osteoclasts, pose major challenges to directed differentiation of stem cells. Ongoing research is advancing from the ability to engineer centimeter-size bone tissue constructs containing viable cells and mineralized matrix to engineering more complex tissue constructs that more closely resemble native bone. It remains to be seen how much can be done (and needs to be done) *in vitro*to obtain bone grafts for implantation, and to study disease and screen cells and therapeutic agents.
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